SEC Form 4 · accession 0000899243-18-015769
Aldeyra Therapeutics, Inc. · ALDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neal Walker
Director
Period of report
Jun 7, 2018
Accepted (ET)
Jun 8, 2018 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001341235
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $8.35 | Jun 7, 2018 | A | 15,526 | A | — | Jun 6, 2028 | Common Stock | 15,526 | 15,526 | D |
| Employee Stock Option (Right to Buy)F2 | $8.35 | Jun 7, 2018 | A | 903 | A | — | Jun 6, 2028 | Common Stock | 903 | 903 | D |
Explanation of responses
- F1Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
- F2Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.